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Mice  develop  delayed-type  hypersensitivity  (DTH) ~ to  heterologous  red 
cells provided  that dose and route of immunization  are  appropriately  chosen 
(1).  No adjuvant  is needed,  but  the hypersensitivity  will be transient  and of 
low intensity if the dose of antigen is too large. For example, the dose of sheep 
red blood cells  (SRBC)  which gives maximum antibody production by intra- 
venous immunization  causes  only a  fleeting and barely discernible  episode of 
hypersensitivity. The suppression of DTH is due to blocking factors which are 
formed by the interaction of antigen and antibody (2). The mediators of DTH 
can be freed from the influence of this normal inhibitory mechanism by splenec- 
tomy  (2),  by  infection  with  BCG  (3),  or  by  treatment  with  drugs  such  as 
cyclophosphamide (CY) which act differentially on B lymphocytes (4-6). Since 
it was known that  DTH  reactions  tend to be more prolonged in  CY-treated 
animals (7, 8), this drug has been used in the present experiments to investigate 
the role of antibody in the regulation of T-cell activity. 
Materials and Methods 
Methods have been described elsewhere for measuring hemagglutinin  titers and DTH (2), 
and lymphoproliferative responses and numbers  of plaque-forming cells (PFC)  in popliteal 
lymph nodes (9, 10). The transfer of DTH with dissociated spleen cells has also been described 
(11). 
Anlmals.--Specific  pathogen-free male and female mice of the CD-1 strain (Charles River 
Breeding Laboratories,  Inc., Wilmington, Mass.) were used at 5 or 6 wk of age. C57BL mice, 
also from a specific pathogen-free colony, were used in one experiment. 
Antigens.--SRBC were obtained from the same animal twice weekly. Cells were collected 
and stored in Alsever's solution at 4°C. They were washed three times with normal saline and 
suspended to known density by hemacytometer count. 
CY.--Cytoxan was donated by Mead Johnson & Co., Evansville, Ind. It was dissolved in 
* Supported by contract no. RFP N01 CP 23221 from the National Cancer Institute and 
grant no. AI-07015 from the National Institute of Allergy and Infectious Diseases, National 
Institutes of Health. 
:~ Eli Lilly International Fellow. 
1  Abbreviations used in  this paper: CY,  cyclophosphamide;  DTH,  delayed-type  hyper- 
sensitivity;  HAG, hemagglutinating  antibody;  PFC, plaque-forming cells; SRBC, sheep red 
blood cells. 
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sterile saline (20 mg/ml) and was administered intravenously as a single dose of 200 mg/kg 
body weight. 
RESULTS 
Effect of CY on the Response to Varying Doses of SRBC.--When varying doses 
of SRBC were given intravenously to normal and CY-treated mice, the latter 
developed high  levels of DTH in  response to  doses  of SRBC  which  caused 
partial  inhibition  and  early decay of DTH in  untreated mice  (Fig.  1).  The 
C57BL mice differed from CD-1 mice used in all other experiments in being 
FIO. i.  Levels of DTH measured on days 4-7 in normal (A--A) and CY-treated (O---@) 
C57BL mice which had been sensitized intravenously with the indicated doses of SRBC. CY 
(200 mg/kg)  was given 2  days  before immunization. The area of  stippling represents the 
augmentation of DTH  attributable to the immunosuppressant action of C¥.  Means of five 
mice. 
less responsive to SRBC  (1,  2).  It was nonetheless apparent that  DTH was 
potentiated because CY suppresses the inhibitory mechanism that is activated 
by a large dose of antigen. 
The Effect of Varying the Interval between CY and Antigen Injections--DTH 
reaches its peak and begins to decay on day 4 in mice immunized in one foot- 
pad with 108 SRBC, the optimum dose for sensitization by this route (1). The 
effect of CY on DTH was therefore measured at two time points, days 4 and 8. 
The drug's immediate influence on the cellular response that leads to the forma- 
tion  of activated  T  cells  could thus  be compared with  its  influence on  the 
normal decay of DTH. 
The average levels of DTH measured on days 4 and 8 in untreated mice im- 
munized with 10  8 SRBC in one hind footpad are indicated by the interrupted 
horizontal lines of Fig. 2. The levels of DTH observed in animals treated with P. H. LAGRANGE,  G. B. MACKANESS,  AND  T. E. MILLER  1531 
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FIG. 2.  Levels of DTH measured on days 4 and 8 in mice sensitized on day To by footpad 
inoculation of 108 SRBC. On the days indicated, mice of separate groups were injected intra- 
venously with CY in a dose equivalent to 200 mg/kg. The interrupted horizontal lines repre- 
sent the mean levels of DTH found on days 4 and 8 in sensitized but untreated mice. Means 
of 5 ~  SEM. 
CY at varying times relative to the same sensitizing dose of SRBC are repre- 
sented by the continuous lines. The effect of CY on the early, or inductive, 
phase of the immune response was biphasic: DTH was potentiated in mice 
given CY before antigenic stimulation and depressed by treatment given after 
immunization. However,  the episode of depressed T-cell  activity had  disap- 
peared by day 8, and been replaced by an impressive degree of enhancement 
except in animals receiving CY on day +4. 
A mean footpad swelling of more than 18 U  (1.8 mm), as recorded on day 8 
in Fig. 2, represents a very gross reaction indeed. Moreover, and in confirma- 
tion of the observations of Turk et al. (7), the reactions elicited in the footpads 
of CY-treated mice persisted for at least 72 h. One such reaction is illustrated 
in the accompanying paper (3). 
Adoptive Transfer of DTIt with Spleen Cells  from C Y-Treated Donors to Normal 
and CY-Treated  Recipients.--The  immediate and very marked depression of 
DTH in animals treated with CY on day +2 suggested that T  cells may not 
be entirely unaffected by this drug. But as circulating monocytes are required 
for the expression of DTH (12), and as CY interferes with the formation of this 
cell type (13),  more evidence was needed. A composite experiment was there- 
fore performed in order to determine whether the phase of depressed reactivity 
in Fig. 2 was due to destruction of specific mediators or to arrested production 
of monocytes. 
Donor mice were immunized intravenously with the optimal sensitizing dose 1532  POTENTIATION  OF  T-CELL-MEDIATED  IM~I.INITY 
of l0  s SRBC. Animals of one donor group (A) were left untreated, and those of 
donor groups B and C were given CY (200 mg/kg) 2 days before or after im- 
munization, respectively. The level of hypersensitivity was measured at the 
time of cell  transfer  (day 4)  in a  sampling of five mice from each panel  of 
donors. Spleen cells from each panel were pooled, and each recipient was given 
one  spleen  equivalent  intravenously  (approximately  10  s  cells)  1  h  before 
testing for DTH. Cells from donor panel B were also used for transfer to CY- 
treated recipients which had been treated with CY (200 mg/kg) at intervals 
ranging from 0 to 5 days before cell transfer. 
As in a previous study (2), the transfer of one spleen equivalent of cells from 
untreated hypersensitive donors (group A)  rendered recipients about half as 
sensitive as were the donors themselves (Fig. 3). Cells from donors treated with 
CY 2 days before immunization (group B) were much more active in trans- 
ferring  hypersensitivity,  though  the  donors  themselves  were  distinctly less 
hypersensitive  at  this  time.  Donors  given  CY  2  days  after  immunization 
(group C) were virtually anergic at the time of cell  transfer and their spleen 
cells failed to confer a significant level of DTH on recipients in whom monocyte 
production was presumably normal (P <  0.2). CY had obviously damaged the 
mediators of DTH in donors of this group. This effect of CY on the specific 
mediators of DTH was convincingly dissociated from effects caused by damage 
to monocyte precursors. The observations recorded on the right in Fig. 3 show 
that DTH reactions could not be elicited at all  in animals given CY 4 days 
before cell transfer. Yet CY remains active in recipients for only about 48 h 
(see Fig. 6).  It follows  that the specific  mediators of DTH would have been 
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FIo.  3.  Left: Levels of DTH  found in the donors  (D)  and the adoptively sensitized re- 
cipients (R) of spleen cells (one spleen equivalent, 1 X  10 s) from mice sensitized intravenously 
with 10  s SRBC 4 days before cell transfer. The donors of group A were untreated, and those 
of group B  and C  received C¥  (200 mg/kg)  2  days before and 2  days after sensitization, 
respectively. Means of 5  :t:  SEM.  Right: Levels of DTH measured in adoptively sensitized 
mice given 10  s spleen cells from donor panel B. The cells were transferred to untreated re- 
cipients (C)  or to recipients on days 0-5 after treatment with CY  (200 mg/kg).  Means of 
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damaged by CY in  this group  of adoptively sensitized recipients. Only the 
absence of another element, presumably the monocyte (12), could explain their 
failure to react. The timing was consistent with this view, for McGregor and 
Koster (13) have shown in rats that the supply of monocytes for mobilization 
into a peritoneal exudate becomes exhausted 4 days after a large single dose of 
CY. But as circulating monocytes do not disappear immediately after treat- 
ment, the depressed reactions observed in recipients given CY at the time of 
transfer, or 1 day later, were probably due to drug damage sustained by specific 
mediators after transfer. 
Development and Persistence of DTH in CY-Treated Mice.--The action of CY 
on the T-cell component of the immune response is clearly most marked in the 
period  immediately surrounding  the  time  of  sensitization.  A  more  detailed 
picture of its influence at this time was obtained by following the development 
and persistence of DTH in groups of mice which were given CY before (T_~), 
with  (To),  or  after  (T+2) sensitization by a  footpad injection of  10  8 SRBC. 
Sensitized, but untreated, controls were tested at each time point. 
Fig. 4 shows that CY caused a marked increase in the level and longevity 
of DTH whether given before, with, or after antigen, but the peak was reached 
at progressively later times. This indicates that the T-cell response is under 
severe constraint for a  well defined period after administration of  CY.  The 
antigenic stimulus from a  footpad inoculation must therefore persist for long 
enough to allow resumption of T-cell induction after the effect of CY has worn 
off. Even when the same dose of SRBC (10 8)  was given intravenously, a  re- 
bound from the suppressive effects of CY occurred, but the ultimate level of 
DTH was much lower (Fig. 5). This presumably means that a larger fraction 
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FiG. 4.  Levels of DTH measured in control and CY-treated mice at intervals after sensiti- 
zation by footpad inoculation of 10 8 SRBC. The times of injecting CY relative to antigen 
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FIG. 5.  Levels of DTH measured in control and CY-treated mice at intervals after sensiti- 
zation by an intravenous injection of 10  s SRBC. The times of injecting CY relative to antigen 
inoculation were as indicated. Means of 5 4- SEM. 
of the immunocompetent pool of precursor T  cells is recruited by intravenous 
immunization and is destroyed by CY given on day +2. 
Effect of CY on the Lymph Node Response to SRBC.--The rates of cell pro- 
liferation ([SH]thymidine incorporation into DNA) and numbers of PFC were 
measured on successive days in the popliteal lymph nodes of mice immunized 
in one hind footpad with 108 SRBC. The node response of untreated  controls 
was compared  with that of mice  given CY  before  (T_~), with (To), or  after 
(T+~) the sensitizing inoculum of SRBC. The corresponding levels  of DTH and 
serum levels of hemagglutinating antibody (HAG) were also measured. 
Fig. 6 A shows that the proliferative response in the popliteal lymph node 
was arrested for about 48 h by CY given at the time of antigen inoculation 
(To). Only in this group was it possible to see how long the drug remains active 
because the effective concentration of drug had already fallen before the onset 
of cell proliferation in mice given CY before antigen (T_2), and the effect was 
so severe when CY was given after antigen (T+2) that cell proliferation never 
resumed a normal pace. 
PFC production and cell proliferation rates were closely correlated. When 
the lymphoproliferative response was delayed by CY, the time taken to reach 
maximum numbers of PFC in the regional node was correspondingly increased 
(Fig. 6 B), and HAG's took longer to appear in the blood (Fig. 6 C). 
The development of DTH was followed for only 8 days (Fig. 6 D), but the 
trends were identical with those recorded in Fig. 4. It seems, therefore, that 
peak levels of hypersensitivity were reached on days 4, 6, 8, and 10 in untreated 
mice and those given CY on days --2, 0, and +2, respectively. P.  H.  LAGRANGE~ G.  B.  MACKAIT£SS~ AND  T.  E.  MILLER 
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FIG. 6. Levels of thymidine incorporation (A) and numbers of direct PFC (B) in poplitea 
lymph nodes of mice treated with CY at various times relative to footpad inoculation with 10  8 
SRBC. The corresponding antibody titers and levels of DTH elicited in the opposite foot are 
recorded in C and D. Means of five mice. 
DISCUSSION 
Humoral and cellular immunity tend to be mutually exclusive (14).  Witness, for 
example, the contrasting responses of normal and splenectomized mice to a massive 
intravenous injection of SRBC: The former produce antibody but no DTH, while the 
latter develop DTH but make little or no antibody (1). This demonstrates, among 
other things, that antigen alone cannot interfere with the function or formation of 
activated T  cells. By way of confirmation, CY-treated mice developed high levels of 
DTH with doses of SRBC that blocked T-cell activity completely in untreated mice 
(Fig.  1). In fact, CY enhanced DTH only to the extent that it released the T-cell 1536  POTENTIATION OF  T-CELL-MEDIATED IM~vrUNITY 
response  from  the  feedback  inhibition  that  normally  accompanies  the  antibody 
response (2). 
The fact that DTH reactions are longer lasting in CY-treated animals  has been 
interpreted as evidence of a differential  effect on T and B cells (5-7), a view that is 
supported by the diminished  B-cell populations found in the blood and  lymphoid 
tissues after treatment (4-6). It is certain, however, that CY does not act exclusively 
on B cells. For one thing, it prolongs the survival of skin allografts (15). And as the 
present findings show, it destroys the mediators of DTH if administered at the right 
time.  Indeed,  as  others have stressed  (16),  timing  critically affects  the  immuno- 
suppression achieved with CY. In the present experiments three different effects were 
obtained by varying the time of treatment in relation to the antigenic stimulus.  A 
single dose of CY which increased the level of T-cell activity (DTH) when given as 
much as 10 days before immunization caused a profound, if transient, depression when 
given 2 days after immunization (Fig.  2). Still later in the immune  response,  when 
DTH was already established,  CY had little apparent effect on T-cell activity apart 
from its influence on monocyte production (Fig. 3). 
r 
The reason for these effects of timing rests  with the mode of action of C¥ 
and the physiological state of participating lymphocyte populations before and 
after becoming engaged by an antigenic stimulus. The proliferative response of 
the popliteal lymph node was delayed for 48 h in mice immunized and treated 
simultaneously with CY (To, Fig. 6 A). This places an upper limit of 2 days on 
the duration of the cytostatic action of CY in the mouse. Yet animals treated 4, 
6,  or even 8  days before immunization developed abnormally high  levels of 
DTH by day 4  (Fig.  2).  CY obviously has a  long-lasting effect on the  cells 
responsible for the  inhibition of T  cells.  Moreover, the  affected cells clearly 
differ from those which mediate DTH in being susceptible at all times to a drug 
that is active only at certain stages of the mitotic cycle (17). They must derive, 
therefore, from rapidly replicating precursors. A  relevant, and once disputed, 
finding of Nossal and M~kel~ (18) showed that a very high ( if not improbable) 
proportion of antibody-secreting cells became labeled by an injection of tritiated 
thymidine given 2 h  before antigen. Though the labeling rates were probably 
inflated by reutilization, this finding gains significance from the fact that bone 
marrow  ]ymphocytes  (predominantly Ig-bearing  B  cells)  have  a  very high 
turnover rate (19) and are a rich source of antibody-forming precursors. More- 
over, Strober has shown that the B  cells which become engaged by a primary 
antigenic stimulus are nonrecirculating cells which are destroyed by a mitotic 
poison (20). 
While an origin in rapidly rel~licating  precursors explains why B cells should 
be so vulnerable to the  toxic action of CY,  and why the T-cell-potentiating 
effect of the drug should be accompanied by a delay in the appearance of PFC 
in regional lymph nodes (Fig. 6 B) and of hemagglutinins in the serum  (Fig. 
6 C),  there is no doubt that  C¥ exerts a  more depressive effect on antibody 
production if given after antigenic stimulation (16). This may be due to inter- 
ference with  helper  cell activity. If helper  cells and  the mediators  of DTH P. H. LAGRANGE,  G. B. MACKANESS,  AND  T. E. MILLER  1537 
belong to the same cell population (21),  they would certainly be damaged by 
CY given 1-3 days after antigen. Although resting T  cells are apparently un- 
affected by CY, those which mediate DTH are clearly vulnerable once they 
have  been  immunologically induced. The  extreme susceptibility of dividing 
cells to the toxicity of CY was revealed by the abrupt cessation of thymidine 
incorporation by responding nodes when CY was given on day +2 (Fig. 6). As 
a result, PFC failed to appear in the regional node, antibody could not be de- 
tected in serum,  and DTH was absent on day 4  when it should have been 
reaching its peak. This last effect was due mainly to destruction of specific 
mediator cells,  as transfer studies showed  (Fig. 3).  It is important to note, 
however, that the T-cell response recovered from the severe depression caused 
by CY given when cells  had begun to divide. Though cells  did not  resume 
proliferation on a  large scale (Fig. 6 A), the output of activated T  cells  was 
enough to support a high level of DTH by day 8 (Fig. 6 D). This must mean 
that the antigenic stimulus from a footpad inoculation persists for long enough 
to recruit a  new batch of precursors  that were not part of the first wave of 
responding T cells, or that some cells recover from the effect of CY and go on to 
proliferate. In either case,  the mediators of DTH obviously must come from 
this new crop of dividing cells. But many potential members of the population 
are undoubtedly annihilated by CY given on day +2, thus explaining why the 
ultimate  levels  of  DTH  are  lower,  especially  in  intravenously immunized 
animals (Fig. 5). The fact that even in these animals DTH reaches a  higher 
level than in untreated controls speaks much for the constraint that is normally 
imposed on the T-cell response by feedback inhibition. Indeed, in attempting 
to raise the general level of T-cell activity by selective immunosuppression one 
is clearly limited by the circumstance that when timing is such as to achieve 
maximum suppression of antibody formation (and hence of feedback inhibition) 
the drug's effect encroaches upon the phase of T-cell proliferation and thus 
restricts the output of activated T cells. It would appear from the data of Fig. 
4  that maximum levels of DTH are achieved when CY and a  subcutaneous 
injection of antigen are given synchronously. Even though this regimen did not 
prevent antibody formation, it did give T cells the longest period of freedom to 
proliferate before antibody-forming cells appeared in the regional  node  where 
most of the activated T cells are presumably made. 
SUMMARY 
Delayed-type hypersensitivity (DTH)  appears in mice immunized with less 
than an optimal immunogenic dose of sheep red blood cells  (SRBC),  but is 
blocked progressively as antibody production increases in response to larger 
doses of SRBC. Treatment with cyclophosphamide (CY) was shown to release 
T  cells from this inhibitory influence of the humoral response, and cause en- 
hancement of DTH. The magnitude of this enhancing effect on T-cell activity 
was  markedly dependent  on  the  time  of  treatment  relative  to  the  time  of 1538  POTENTIATION  OF  T-CELL-MEDIATED  I~IMUNITY 
immunization,  and on the  time chosen for measuring DTH. The reasons for 
these pronounced effects of timing are threefold: (a) CY given before antigenic 
stimulation has a  long-lasting effect on antibody formation, but no apparent 
effect on the precursors of activated T  cells. (b) After antigenic stimulation, T 
cells also become susceptible to CY. (c) The production of a nonspecific partici- 
pant  (monocyte) in the DTH reaction is also suppressed by CY,  though  the 
supply of circulating monocytes is not immediately affected by the  drug. 
The differential effect of CY on T  and B  lymphocytes depends on the dif- 
fering  physiological  states  of  the  majority  of  cells  that  make  up  these  two 
populations. The former are resting cells that are insensitive to CY until  ex- 
posed to specific antigen, while the latter are drawn from a rapidly replicating 
precursor pool and are susceptible to CY at all times. 
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